Background Obesity is a chronic disease that results in substantial global morbidity and
mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic …

Objective Obesity is a growing global concern compounded by limited availability of effective
treatment options. The SURMOUNT development program aims to evaluate the efficacy and …

Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Background Recent studies suggest that tirzepatide, a dual glucose-dependent
insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Objectives Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-
like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis …

Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐
escalation regimens in patients with type 2 diabetes. Materials and Methods In this double …

Objective Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight …

Tirzepatide is a novel glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …